Are FDA’s Approval Authority and Agency Deference at Risk? Mifepristone Ruling and Beyond

The Food and Drug Law Institute (FDLI) recently held its 2023 Annual Conference on May 17-18 in Washington, D.C. where professionals from the food, drug, medical device, biologics, and tobacco industries gathered to hear important updates and panel discussions from a distinguished group of industry and FDA speakers.  The Conference commenced with keynote addresses by […]

Read More